MDGL Share Price Performance
US$302.17
42.72 (16.47%)
28.9% undervalued intrinsic discount
US$425.00
Fair Value
Price US$302.17
AnalystConsensusTarget US$425.00
Fair ValueUS$425.00
Share PriceUS$302.17
28.9% undervalued intrinsic discount
MDGL Community Narratives
AN
Fair Value US$425.00 28.9% undervalued intrinsic discount
FDA Approval Will Expand MASH Treatment Market Reach
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
MDGL Community Fair Values
- AN
Consensus Narrative from 14 AnalystsFDA Approval Will Expand MASH Treatment Market Reach
Key Takeaways First FDA-approved MASH treatment and strong U.S. market launch position Madrigal Pharmaceuticals for significant revenue growth. Strategic team enhancements and international market expansion efforts could bolster efficiencies and enhance future net margins.US$425.00FV28.9% undervalued intrinsic discount83.71%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative6users have followed this narrative11 days ago author updated this narrative
Recent MDGL News & Updates
No updates
Madrigal Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 05, 2025
- Earnings per share (EPS)
- -17.64
- Gross Margin
- 96.61%
- Net Profit Margin
- -123.38%
- Debt/Equity Ratio
- 16.6%
Madrigal Pharmaceuticals, Inc. Competitors
About MDGL
- Founded
- n/a
- Employees
- 528
- CEO
- WebsiteView website
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 11.4%
- 1 Year: 20.5%
- Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a pullback of 2.4% in the Information Technology sector. In contrast to the last week, the market is actually up 20% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading